Verastem Inc
VSTM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$986.14M
Close$
$-6.66
167.6% downside
Current Fair Value
167.6% downsideOvervalued by 167.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $986.14 Million |
|---|---|
| Enterprise Value | $926.18 Million |
| Earnings per Share | $-3.02 |
| Beta | 0.32 |
| Outstanding Shares | 100,116,000 |
Return
| Return on Equity | -405.51% |
|---|---|
| Return on Assets | -98.15% |
| Return on Invested Capital | -124.47% |
Valuation & Multiples
| P/E Ratio | -3.96 |
|---|---|
| PEG | -11.76 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.58 |
| Enterprise Value to EBIT | -5.8 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.44
Consensus analyst estimateRevenue Estimate
$26.57 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 266.34% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.59%▼ 94.67% |
|---|---|
| Total Invested | $4.76M▼ 98.70% |
| Investors Holding | 14▼ 153.00% |
About Verastem Inc
102 employees
CEO: Brian Stuglik
Verastem, Inc. is an emerging biopharmaceutical firm dedicated to the discovery, development, and eventual commercialization of innovative therapies targeting various cancers. Central to its pipeline is VS-6766, an investigational compou...